|
Research Management and Support
|
RMS ES 2018
|
$340,640,887
|
N/A
|
National Institutes of Health
|
|
Topic 371 - Phase I SBIR Contract - Valudation and Optimization of RP-185 as Adjuvant to Exploit the Immune Response Generated by Radiation
|
261201800023C
|
$299,847
|
-, -
|
RIPTIDE BIOSCIENCE, INC.
|
|
Identifying molecular drivers of tumor heterogeneity in pancreatic cancer
|
1F31CA224792-01A1
|
$36,672
|
ADAMS, CHRISTINA
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
3R01CA195708-05S1
|
$94,087
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Molecular mechanism of bitter melon juice efficacy against pancreatic cancer.
|
5R01CA195708-05
|
$382,616
|
AGARWAL, RAJESH
|
UNIVERSITY OF COLORADO DENVER
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
3U10CA180791-04S1
|
$145,357
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Network Lead Academic Participating Site: Memorial Sloan-Kettering Cancer Center
|
5U10CA180791-05
|
$922,200
|
AGHAJANIAN, CAROL
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation
|
4R44CA203336-02
|
$659,516
|
AGUILAR-CORDOVA, ESTUARDO
|
ADVANTAGENE, INC
|
|
Functional interrogation of epigenetic vulnerabilities in KRAS-mutant pancreatic cancer
|
5K08CA218420-02
|
$177,120
|
AGUIRRE, ANDREW
|
DANA-FARBER CANCER INST
|
|
Role of Nix in pancreatic ductal adenocarcinoma
|
5F30CA200240-03
|
$49,524
|
ALAGESAN, BRINDA
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
ATBC Study
|
ZIA CP010195 03031
|
$738,165
|
Albanes, Demetrius
|
DCEG (NCI)
|
|
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic Site
|
5U10CA180790-05
|
$1,223,634
|
ALBERTS, STEVEN
|
MAYO CLINIC ROCHESTER
|
|
Mesothelin-targeted immunotoxins in Pancreatic Cancer
|
ZIA BC 011652
|
$700,006
|
Alewine, Christine
|
CCR (NCI)
|
|
Clinical Support
|
ZIE BC 011653
|
$7,071
|
Alewine, Christine
|
CCR (NCI)
|
|
Profiling signaling activity and gene expression in single, pancreatic adenocarcinoma cells using CE-RNA-Seq
|
1R01CA224763-01A1
|
$575,272
|
ALLBRITTON, NANCY
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
|
Dosage-Dependent Hedgehog Signaling in Pancreatic Cancer
|
5R01CA198074-04
|
$378,171
|
ALLEN, BENJAMIN
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas
|
7R01CA182076-05
|
$339,622
|
ALLEN, PETER
|
DUKE UNIVERSITY
|
|
Novel Strategies for Precision T-cell Therapies
|
3R01CA198095-03S1
|
$107,431
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Novel Strategies for Precision T-cell Therapies
|
5R01CA198095-03
|
$520,564
|
ALMO, STEVEN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Inherited bone marrow failure syndromes study
|
ZIA CP010144 07130
|
$1,652,758
|
Alter, Blanche
|
DCEG (NCI)
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S1
|
$142,498
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
3P30CA010815-49S2
|
$200,000
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Consolidated Basic Cancer Research Program
|
5P30CA010815-49
|
$2,645,581
|
ALTIERI, DARIO
|
WISTAR INSTITUTE
|
|
Biochemical Analysis of Multidrug Resistance-linked Transport Proteins
|
ZIA BC 010030
|
$753,084
|
Ambudkar, Suresh
|
CCR (NCI)
|
|
Reprogramming Tumor-Associated Macrophages in PDAC with MicroRNA Nano-Vectors
|
5R21CA213114-02
|
$217,282
|
AMIJI, MANSOOR
|
NORTHEASTERN UNIVERSITY
|
|
The Genetics of Pancreatic Cancer Susceptibility_Amundadottir
|
ZIA CP010201 10569
|
$752,429
|
Amundadottir, Laufey
|
DCEG (NCI)
|
|
Hutchinson Center as Lead Academic Participating Site (U10)
|
5U10CA180828-05
|
$605,293
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Identification of genomic regulatory elements in pancreas cells
|
ZIA BC 011798
|
$800,611
|
Arda, Hatice
|
CCR (NCI)
|
|
2/2 SDSU/UCSD Cancer Center Comprehensive Partnership
|
5U54CA132384-09
|
$1,192,031
|
ARREDONDO, ELVA
|
SAN DIEGO STATE UNIVERSITY
|
|
Stanford Cancer Institute
|
3P30CA124435-11S1
|
$248,520
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Stanford Cancer Institute
|
3P30CA124435-11S2
|
$171,518
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Stanford Cancer Institute
|
5P30CA124435-11
|
$3,334,464
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Reversing Cellular immortality in cancer
|
5R35CA197563-04
|
$962,915
|
ARTANDI, STEVEN
|
STANFORD UNIVERSITY
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
3P30CA142543-09S1
|
$249,371
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
5P30CA142543-09
|
$2,480,000
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
T Cell Alternative p38 Activation Pathway
|
ZIA BC 010774
|
$298,466
|
Ashwell, Jonathan
|
CCR (NCI)
|
|
Cancer Center Support Grant
|
2P30CA082103-19
|
$7,954,381
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S1
|
$84,000
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S2
|
$206,488
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-19S3
|
$257,838
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Integrative approaches to elucidate p53 transcriptional networks during carcinogenesis
|
5R35CA197591-04
|
$977,640
|
ATTARDI, LAURA
|
STANFORD UNIVERSITY
|
|
Clinical Translation of Nuclear Export Inhibitor in Metastatic Pancreatic Cancer
|
1R37CA215427-01A1
|
$352,275
|
AZMI, ASFAR
|
WAYNE STATE UNIVERSITY
|
|
Obesity and Pancreatic Cancer Progression and Survival
|
1K07CA222159-01A1
|
$149,125
|
BABIC, ANA
|
DANA-FARBER CANCER INST
|
|
Biophotonics to Couple Pancreatic with Upper GI Screening via Ultrathin Endoscopy
|
5R01CA183101-04
|
$620,486
|
BACKMAN, VADIM
|
NORTHWESTERN UNIVERSITY
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
2P30CA014520-44
|
$4,590,130
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
3P30CA014520-44S1
|
$250,000
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
3P30CA014520-44S2
|
$136,232
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
3P30CA014520-44S3
|
$75,711
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
UW Comprehensive CANCER CENTER SUPPORT
|
3P30CA014520-44S4
|
$31,772
|
BAILEY, HOWARD
|
UNIVERSITY OF WISCONSIN-MADISON
|
|
IKK/NF-kappaB Signaling in Cancer: Therapy, Resistance, and Tumor Initiating Cells
|
5R35CA197684-03
|
$848,325
|
BALDWIN, ALBERT
|
UNIV OF NORTH CAROLINA CHAPEL HILL
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|